Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.21.1
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2019
Licensing and other arrangements        
Revenue from contracts with customers   $ 19 $ 500  
Janssen Biotech Inc. | License Agreement        
Licensing and other arrangements        
Cash payment received $ 2,500      
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events $ 3,000      
Percentage of royalty on worldwide net sales of each product upon commercialization 0.75%      
Revenue from contracts with customers   0 $ 0 $ 2,500
Contract assets   0    
Contract liabilities   0    
Capitalized contract costs   $ 0